Home
Boehringer Ingelheim

Boehringer Ingelheim Market Share Analysis for July 2026

Pets and Animals > Pet Food and Supplies

Domainboehringer-ingelheim.es

Year Founded1885

Employees> 10001

Annual Revenue> $1B

Boehringer Ingelheim

Boehringer Ingelheim (including company regionals)

boehringer-ingelheim.es

See more website traffic and engagement information

Boehringer Ingelheim Revenue up to July 2026 is > 1B

revenue generated by Boehringer Ingelheim top domains

Boehringer Ingelheim top domains revenue over 3 years

Revenue for Boehringer Ingelheim top domains

boehringer-ingelheim.es> 1B

See more with Sales Intelligence

Total visits to Boehringer Ingelheim's top domains

Understand Boehringer Ingelheim market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

boehringer-ingelheim.es653

See more with Sales Intelligence

Avg. visit duration in Boehringer Ingelheim's top domains

Analyze Boehringer Ingelheim engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Boehringer Ingelheim's top domains

See how Boehringer Ingelheim keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

boehringer-ingelheim.es1.00

See more with Sales Intelligence

Boehringer Ingelheim top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Boehringer Ingelheim

These are the website technologies, by industry, used by Boehringer Ingelheim top domains

Conversion & Analytics (7)

Google Analytics

Social (4)

Instagram

Audio Video Media (3)

YouTube

Content Management System (2)

Drupal

More Technologies

8

See all

News & Signals from Boehringer Ingelheim

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBoehringer Ingelheim launched Phase III data from the InPedILD trial on Sep 5th '22.Full data were published in the European Respiratory Journal and presented at the European Respiratory Society International Congress in Barcelona, Spain RIDGEFIELD, Conn. and INGELHEIM, Germany, Sept. 5, 2022 /PRNewswire/ -- Today, Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of nintedanib (OFEV ® ) in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease (ILD).

NewsAsahi Glass Co. partners with Boehringer Ingelheim.AGC Inc., a world-leading manufacturer of glass, chemicals and high-tech materials, has entered into an agreement with Boehringer Ingelheim to acquire its subsidiary Malgrat Pharma Chemicals, S.L.U. (MPC).